A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib

计划入组 955 人 · 首次发布于 2019 年 11 月 20 日

Hyperthermia Combined With Immune Checkpoint Inhibitor Therapy for Advanced Gastrointestinal Tumours

计划入组 18 人 · 首次发布于 2023 年 9 月 5 日

Protection Against Benzene Toxicity

首次发布于 2001 年 2 月 23 日

KRAS program (BeiGene)

STING modulators (Beigene)

IRAK4 PROTAC(BeiGene)

BeiGene Ltd.

China

BEIGENE USA, INC.

United States

BeiGene Ireland Ltd.

Ireland

Novartis Partners with BeiGene for TIGIT Drug Development

BeiGene Expands Oncology Clinical Trials in Brazil to Address Unmet Needs

BeiGene Advances Global Cancer Treatment with Innovative Therapies